Skip to content

Annexon ANNX Investment Proceeds

Investment Proceeds at other companies

Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$104.63M+27.4%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$101.48M+46.4%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$35M-74.5%
Jade Biosciences, Inc. Common Stock logo
Jade Biosciences, Inc. Common StockJBIO
$65.43M+409%
Janux Therapeutics logo
Janux TherapeuticsJANX
$121.31M+288%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's investment proceeds?
Annexon (ANNX) reported investment proceeds of $33M in Q1 2026.
How has Annexon's investment proceeds changed year-over-year?
Annexon's investment proceeds decreased by 79.3% year-over-year, from $159.5M to $33M.
What is the long-term trend for Annexon's investment proceeds?
Over 3 years (2022 to 2025), Annexon's investment proceeds has grown at a 31.2% compound annual growth rate (CAGR), from $178.17M to $402.4M.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.